Low-dose decitabine (a DNA demethylation drug) combined with PD-1 inhibitors can promote the expansion and effector function of CD8+ exhausted precursor T cells by maintaining the activity of the AP-1/JunD pathway, thus achieving more potent and durable anti-tumor activity. Here, JUN is linked to neoplasm.